Lisata Therapeutics Inc - LSTA STOCK NEWS

IMPACT

SENTIMENT

10/17/2023 08:00 AM

LSTA : Nasdaq

Lisata Therapeutics Announces European Medicines Agency Has Granted LSTA1 Orphan Drug Designation for the Treatment of Pancreatic Cancer

IMPACT

SENTIMENT

09/28/2023 08:00 AM

LSTA : Nasdaq

Lisata Therapeutics Announces Participation in Upcoming Conferences in October

IMPACT

SENTIMENT

09/20/2023 08:00 AM

LSTA : Nasdaq

Lisata Therapeutics Announces Participation in InfoSec World 2023

IMPACT

SENTIMENT

09/12/2023 08:00 AM

LSTA : Nasdaq

Lisata Therapeutics Announces First Patient Treated in the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide, in Patients with Advanced Solid Tumors

IMPACT

SENTIMENT

09/06/2023 08:00 AM

LSTA : Nasdaq

Lisata Therapeutics Announces Outcome of Interim Futility Analysis for its Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma

IMPACT

SENTIMENT

09/05/2023 08:00 AM

LSTA : Nasdaq

Lisata Therapeutics Announces Participation in Upcoming Conferences in September

IMPACT

SENTIMENT

08/15/2023 08:30 AM

LSTA : Nasdaq

Impilo Therapeutics Launches to Enable Nucleic Acid-Based Medicines to Effectively Treat Solid Tumor Cancers

IMPACT

SENTIMENT

08/14/2023 04:05 PM

LSTA : Nasdaq

Lisata Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

IMPACT

SENTIMENT

08/08/2023 08:00 AM

LSTA : Nasdaq

Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Malignant Glioma

IMPACT

SENTIMENT

08/07/2023 08:30 AM

LSTA : Nasdaq

Lisata Therapeutics to Report Second Quarter 2023 Financial Results on Monday, August 14 After Market Trading and to Host Conference Call on Tuesday, August 15 at 8:30 a.m. Eastern Time

Lisata Therapeutics Inc

Nasdaq:LSTA

LSTA Stock Data

Industry Biological Product (except Diagnostic) Manufacturing

Sector Manufacturing

Website Link

About LSTA

caladrius biosciences, inc., a clinical-stage biopharmaceutical company, develops cellular therapeutic product candidates to address diseases and conditions caused by ischemia. its product candidates include developmental treatments for cardiovascular diseases, such as clbs12 for the treatment of critical limb ischemia; clbs16, which is in phase ii clinical trial for the treatment of coronary microvascular dysfunction; clbs14, a regenerative medicine advanced therapy for treating no-option refractory disabling angina. the company was formerly known as neostem, inc. and changed its name to caladrius biosciences, inc. in june 2015. caladrius biosciences, inc. was founded in 1980 and is headquartered in basking ridge, new jersey.